GoodRx Subscription Revenue Jumps 39% as Strategy Shifts
Aug 11, 2026GoodRx is shifting more product and marketing investment toward subscriptions as prescription-transaction revenue declines.
GoodRx is giving subscriptions a larger role in its relationship with consumers.
Subscription revenue increased 39% year over year to $28.5 million in the second quarter.
At the same time, prescription-transaction revenue fell 26% to $106.4 million, from $143.1 million a year earlier.
GoodRx said part of that decline came from changes in the retail pharmacy market, including store closures and lower volume in one of its savings programs. The company also made a deliberate choice to shift more product and marketing investment toward subscriptions.
Pharma Direct is growing quickly too, with Q2 revenue up 76% to $61.6 million. Together, Pharma Direct and subscriptions are helping offset pressure in GoodRx’s traditional prescription-transaction business.
Subscription Revenue Is Growing Faster Than Plan Count
GoodRx said much of its subscription growth came from condition-specific programs, especially weight loss.
Subscription plans increased 14% year over year, compared with the 39% increase in subscription revenue.
Management viewed that gap as encouraging, although GoodRx does not report average revenue per subscription plan.
The company also has not disclosed churn or retention for its condition-specific subscriptions or its newer GoodRx Companion membership.
Total Q2 revenue was $200.4 million, down 1% year over year.
GoodRx raised its full-year 2026 outlook and now expects revenue of $790 million to $805 million.
GoodRx Companion Takes a Bigger Role
GoodRx launched Companion in May as a broader healthcare membership alongside its condition-specific subscriptions.
The $14.99-per-month membership includes more than 200 common generic medications for $0, plus discounted online care and other health services.
GoodRx has described Companion as a way to build a more continuous relationship with consumers beyond individual prescription transactions.
During the Q2 earnings call, CEO Wendy Barnes said GoodRx Gold will remain available, while Companion is becoming the company’s primary subscription offering.
Subscriptions are also getting more visibility across GoodRx’s website, including its homepage and drug-price pages.
Management said it is still building customer-acquisition and retention programs around Companion. The focus for now is laying the groundwork for longer-term subscription growth rather than pushing for the highest possible subscription revenue in 2026.
An Older GoodRx Metric Tells Less of the Story
GoodRx averaged 5 million monthly active consumers during the quarter, down 12% year over year.
The company tied the decline to retail-pharmacy changes, seasonality in one of its savings programs and its shift toward subscriptions.
GoodRx has also acknowledged that monthly active consumers are becoming a less complete measure of its performance because the metric reflects the prescription-transaction business rather than its growing subscription activity.
As the revenue mix changes, GoodRx is evaluating whether it needs different measures to track business performance.
INSIDER TAKE
For years, much of GoodRx’s consumer relationship revolved around a transaction. Someone needed a prescription, checked a price and used GoodRx to save money.
A subscription gives GoodRx more opportunities to stay connected between those individual purchases.
That makes the shift toward Companion and condition-specific subscriptions worth watching. GoodRx is directing more product and marketing resources toward recurring relationships, while subscription revenue is growing faster than plan count.
There are still important blanks.
GoodRx hasn’t disclosed retention or churn for Companion or its condition-specific programs. We also don’t know acquisition cost, payback or lifetime value for these subscribers.
Those numbers will become more important if subscriptions keep growing. Fast revenue growth is encouraging. Operators still need to know whether customers stay and whether the economics improve as the programs scale.
GoodRx’s changing KPIs are another signal. Monthly active consumers made sense when prescription transactions told more of the company’s story. As subscriptions grow, that metric captures less of the business.
Subscription operators face the same issue when their models evolve. A familiar KPI can keep moving in the wrong direction even when the underlying business is changing in ways that require a different measure.
GoodRx has made the direction clear. Now we need to see the retention and customer economics behind the growth.
Related Member Resource
GoodRx’s shift toward subscriptions shows how paid membership can change customer relationships, revenue patterns, and the economics behind growth. For a deeper look at what operators should evaluate:
Sources
Reported by:
